Conference Call to Be Held Tomorrow, Wednesday, September 26th at 8:30am
NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it will conduct a conference call to discuss a strategic alliance surrounding one of its Phase II portfolio products for a territory outside the US.
The call will take place tomorrow, Wednesday, September 26, 2007, at 8:30am EDT. Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals will host the call.
Interested parties may participate in the call by dialing 1-877-719-9796 (U.S.), 1-719-325-4777 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening diseases,
including diabetes and cancer. Keryx's lead compound under development is
Sulonex(TM) (sulodexide), previously referred to as KRX-101, a
first-in-class, oral heparinoid compound for the treatment of diabetic
nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex
is in a pivotal Phase III and Phase IV clinical program under a Special
Protocol Assessment with the Food & Drug Administration. Additionally,
Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound
that has the capacity to bind phosphate and form non-absorbable complexes.
Zerenex is currently in Phase II clinical development for the treatment of
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved